Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jul 25;13(7):e0199675.
doi: 10.1371/journal.pone.0199675. eCollection 2018.

Prognostic Significance of CIP2A Expression in Solid Tumors: A Meta-Analysis

Free PMC article

Prognostic Significance of CIP2A Expression in Solid Tumors: A Meta-Analysis

Min Tang et al. PLoS One. .
Free PMC article


CIP2A, cancerous inhibitor of protein phosphatase 2A, was initially recognized as an oncoprotein. Recently several studies revealed that CIP2A could function as a prognosis biomarker, however, the result remained not comprehensive, partly due to small number of patients included individually. Here we carried out a meta-analysis of published studies to assess the prognostic significance of CIP2A in solid tumors. All eligible studies were identified through searching PubMed, Embase and Web of Science database. In this meta-analysis, 22 studies involving 4,579 participants were included, and we verified that CIP2A over-expression was significantly related with poor overall survival (pooled HR = 1.844, 95% CI = 1.528-2.225, P<0.001) and short disease free survival (pooled HR = 1.808, 95% CI = 1.591-2.055, P<0.001) in solid tumors. Additionally, subgroup analysis suggested that the trend of a poor overall survival with an increased CIP2A expression was present in East-Asian and European patients, as well as in lung cancer and colorectal cancer. To sum up, CIP2A over-expression was associated with poor survival in human solid tumors and might be a predictive factor of poor prognosis.

Conflict of interest statement

The authors have declared that no competing interests exist.


Fig 1
Fig 1. The flow chart of the selection process in our meta-analysis.
Fig 2
Fig 2. The correlation between CIP2A expression and overall survival (OS) in solid tumors.
Fig 3
Fig 3. The correlation between CIP2A expression and disease free survival (DFS) in solid tumors.
Fig 4
Fig 4. Begg’s funnel plots for the studies involved in the meta-analysis.
(A) overall survival (B)disease free survival. Abbreviations: loghr, logarithm of hazard ratios; s.e., standard error.
Fig 5
Fig 5. Sensitivity analysis of the meta-analysis.
(A) overall survival (B) disease free survival.

Similar articles

See all similar articles

Cited by 3 articles


    1. Ostman A, Hellberg C, Bohmer FD. Protein-tyrosine phosphatases and cancer. Nature reviews Cancer. 2006;6(4):307–20. Epub 2006/03/25. 10.1038/nrc1837 . - DOI - PubMed
    1. Eichhorn PJ, Creyghton MP, Bernards R. Protein phosphatase 2A regulatory subunits and cancer. Biochimica et biophysica acta. 2009;1795(1):1–15. Epub 2008/07/01. 10.1016/j.bbcan.2008.05.005 . - DOI - PubMed
    1. Ruvolo PP. The broken “Off” switch in cancer signaling: PP2A as a regulator of tumorigenesis, drug resistance, and immune surveillance. BBA clinical. 2016;6:87–99. 10.1016/j.bbacli.2016.08.002 - DOI - PMC - PubMed
    1. Sangodkar J, Farrington CC, McClinch K, Galsky MD, Kastrinsky DB, Narla G. All roads lead to PP2A: exploiting the therapeutic potential of this phosphatase. The FEBS journal. 2016;283(6):1004–24. Epub 2015/10/29. 10.1111/febs.13573 . - DOI - PMC - PubMed
    1. Soo Hoo L, Zhang JY, Chan EK. Cloning and characterization of a novel 90 kDa 'companion' auto-antigen of p62 overexpressed in cancer. Oncogene. 2002;21(32):5006–15. Epub 2002/07/16. 10.1038/sj.onc.1205625 . - DOI - PubMed

Publication types

Grant support

National Natural Science Foundation 81472786 and 81773192, Natural Science Foundation of Jiangsu Province BK20171248, Jiangsu Province Youth Medical Talents Project, QNRC2016527, the Foundation of tumor clinical and basic research team KYC005, and Suzhou City Health Science and Technology Project LCZX201619 to MBC. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.